Anti-inflammatory and Antioxidant Effects of Silibinin on Valproate-Induced Pancreatitis in Male Wistar Rats.

IF 2
Mohammad Hady Khosravi, Khairollah Asadollahi, Bahareh Ghiasi, Amir Adibi, Somayeh Heidarizadi, Monireh Azizi
{"title":"Anti-inflammatory and Antioxidant Effects of Silibinin on Valproate-Induced Pancreatitis in Male Wistar Rats.","authors":"Mohammad Hady Khosravi, Khairollah Asadollahi, Bahareh Ghiasi, Amir Adibi, Somayeh Heidarizadi, Monireh Azizi","doi":"10.2174/0118715303411821250914094338","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Valproic acid (VPA), a widely used antiepileptic drug, is associated with pancreatic toxicity. Silibinin, the active component of silymarin, exhibits antioxidant/anti-inflammatory properties. This study investigated silibinin's protective effects against VPA-induced pancreatitis.</p><p><strong>Methods: </strong>48 male Wistar rats (250-280 g) were divided into 8 groups (n=6): control, VPA-only (150,300 and 450 mg/kg), silibinin-only (150 mg/kg), and co-treatment groups. After 3 weeks, biochemical markers (amylase, lipase, SOD, CAT, TNF-α, IL-6) and histopathology (H&E staining) were analyzed. Data were compared using ANOVA/Tukey's test (p<0.05 significant).</p><p><strong>Results: </strong>VPA dose-dependently increased pancreatic enzymes and inflammatory markers, while reducing antioxidants. Silibinin co-treatment significantly attenuated these effects: Reduced amylase (642.8→375.6 U/L at 450 mg/kg VPA) and TNF-α (61.0→31.6 pg/mL) and restored SOD (10.9→18.3 U/mg) and CAT (5.3→366.2 U/mg). Histopathology confirmed reduced inflammation/ necrosis in co-treatment groups (p<0.01).</p><p><strong>Discussion: </strong>Silibinin mitigated VPA-induced pancreatitis via antioxidant (SOD/CAT upregulation) and anti-inflammatory (TNF-α/IL-6 reduction) mechanisms. The effect was dose-dependent, with optimal protection at lower VPA doses (150 and 300 mg/kg).</p><p><strong>Conclusion: </strong>Silibinin shows promise as an adjunct therapy to reduce VPA-associated pancreatic damage. Further clinical studies are warranted.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715303411821250914094338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Valproic acid (VPA), a widely used antiepileptic drug, is associated with pancreatic toxicity. Silibinin, the active component of silymarin, exhibits antioxidant/anti-inflammatory properties. This study investigated silibinin's protective effects against VPA-induced pancreatitis.

Methods: 48 male Wistar rats (250-280 g) were divided into 8 groups (n=6): control, VPA-only (150,300 and 450 mg/kg), silibinin-only (150 mg/kg), and co-treatment groups. After 3 weeks, biochemical markers (amylase, lipase, SOD, CAT, TNF-α, IL-6) and histopathology (H&E staining) were analyzed. Data were compared using ANOVA/Tukey's test (p<0.05 significant).

Results: VPA dose-dependently increased pancreatic enzymes and inflammatory markers, while reducing antioxidants. Silibinin co-treatment significantly attenuated these effects: Reduced amylase (642.8→375.6 U/L at 450 mg/kg VPA) and TNF-α (61.0→31.6 pg/mL) and restored SOD (10.9→18.3 U/mg) and CAT (5.3→366.2 U/mg). Histopathology confirmed reduced inflammation/ necrosis in co-treatment groups (p<0.01).

Discussion: Silibinin mitigated VPA-induced pancreatitis via antioxidant (SOD/CAT upregulation) and anti-inflammatory (TNF-α/IL-6 reduction) mechanisms. The effect was dose-dependent, with optimal protection at lower VPA doses (150 and 300 mg/kg).

Conclusion: Silibinin shows promise as an adjunct therapy to reduce VPA-associated pancreatic damage. Further clinical studies are warranted.

水飞蓟宾对丙戊酸诱导的雄性Wistar大鼠胰腺炎的抗炎和抗氧化作用。
简介:丙戊酸(VPA)是一种广泛使用的抗癫痫药物,与胰腺毒性有关。水飞蓟素的活性成分水飞蓟宾具有抗氧化/抗炎特性。本研究探讨水飞蓟宾对vpa诱导的胰腺炎的保护作用。方法:48只雄性Wistar大鼠(250 ~ 280 g)分为8组(n=6):对照组、单剂量vpa组(150、300、450 mg/kg)、单剂量水飞蓟宾组(150 mg/kg)和共处理组。3周后进行生化指标(淀粉酶、脂肪酶、SOD、CAT、TNF-α、IL-6)和组织病理学(H&E染色)分析。数据采用方差分析/Tukey检验进行比较(结果:VPA剂量依赖性地增加胰腺酶和炎症标志物,同时降低抗氧化剂。水飞蓟宾共处理显著降低了这些作用:降低了淀粉酶(450 mg/kg VPA下642.8→375.6 U/L)和TNF-α(61.0→31.6 pg/mL),恢复了SOD(10.9→18.3 U/mg)和CAT(5.3→366.2 U/mg)。组织病理学证实,联合治疗组炎症/坏死减少(p讨论:水飞蓟宾通过抗氧化(SOD/CAT上调)和抗炎(TNF-α/IL-6降低)机制减轻vpa诱导的胰腺炎。效果是剂量依赖性的,较低VPA剂量(150和300 mg/kg)的保护效果最佳。结论:水飞蓟宾有希望作为一种辅助治疗来减少vpa相关的胰腺损伤。进一步的临床研究是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信